Licensing status

Publication and contact information

Gastrointestinal disease



Cell culture and mouse studies suggest antagonizing CD38 could be useful for treating pancreatitis. In cultured mouse pancreatic acinar cells, Cd38 deletion decreased calcium release and cell injury in response to excessive stimulation compared with wild-type Cd38 expression. In a mouse model of bile acid-induced pancreatitis, Cd38 knockout mice had less damage than wild-type mice. Next steps include testing CD38 mAbs in cellular and mouse models of pancreatitis.
Anti-CD38 mAbs in Phase I/II testing for multiple myeloma (MM) include MOR202 from Celgene Corp. and MorphoSys AG, daratumumab from Genmab A/S and Johnson & Johnson and SAR650984 from Sanofi.

SciBX 6(38); doi:10.1038/scibx.2013.1064
Published online Oct. 3, 2013

Patent and licensing status undisclosed

Orabi, A.I. et al. J. Biol. Chem.; published online Aug. 12, 2013;
Contact: Sohail Z. Husain, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa.